Cannabidiol/tetrahydrocannabinol - PhytoTech Therapeutics

Drug Profile

Cannabidiol/tetrahydrocannabinol - PhytoTech Therapeutics

Alternative Names: PNL-THC:CBD; PTL 201

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MMJ PhytoTech
  • Class Analgesics; Antiemetics; Antispasmodics; Anxiolytics; Appetite stimulants; Cannabinoids; Muscle relaxants; Neuroprotectants; Phytotherapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists; Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 03 Jan 2017 Preclinical trials in Multiple sclerosis in Israel (PO) before January 2017 (MMJ PhytoTech pipeline, January 2016)
  • 25 Dec 2016 PhytoTech Therapeutics plans a phase II trial for Multiple sclerosis in Israel (NCT03005119)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top